MP Advisors is an independent company offering research and paramount knowledge within a healthcare industry. At present great many global pharmaceutical companies, especially in U.S., Europe, Russia, India and Japan are among MP Advisors’s clients. When founded, 1996, the agency is ensuring investment solutions and assessing investment opportunities with a penetrating eye on risks and benefits from funding pharma manufacturing.
MP Advisors unparalleled service includes:
- Financial Analysis;
- Competitive landscaping;
- Macro Analysis;
- Technology Transfer;
- Mergers & Acquisitions;
- Strategic planning;
- Forecast.
Customized reports are in the focus area of skillful and competent experts who explore, analyze and interpret data, select tools and approaches on how efficiently reach ultimate market decisions and reach maximum understanding of current biotech and therapeutic issues.
More than 200 medical companies’ profiles are in its database. MP Advisors publishes insightful reports fortified by proficient views of key specialists. Moreover, it produces ad hoc reports on Japan and Indian generic drug, Para IV, oncology, obesity and other therapy reviews.
Publications found:
456
Sort by:
MORPHOSYS (MOR) - MOR103/ MOR202 - Partnering is the Beginning of a New Phase of Growth
US$ 140.00
Alliances with GSK and Celgene in 2013 propelled MorphoSys (MOR) in the limelight. This could well be the inflection point in MorphoSys's evolution into a successful mature ... , please read our report released on September 12, 2013, titled, “MOR103/ MOR202 – Partnering is the Beginning of a New Phase of Growth ”.
September 2013
5 pages
Generic Advair - 3 years to go, but which generic companies are better poised?
US$ 140.00
... announced the draft guidance for the development of generic version of GSK’s Asthma / COPD drug – Advair (Fluticasone propionate + Salmeterol Xinafoate). The ... guidelines pave the way for generic companies to launch a substitutable and interchangeable version of Advair in the US market, which should ...
September 2013
3 pages
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1,2, STELARA, GSK-1605786, Vercirnon, Traficet-EN
US$ 250.00
Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing ...
September 2013
7 pages
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1,2, STELARA, GSK-1605786, Vercirnon, Traficet-EN
US$ 250.00
Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing ...
September 2013
7 pages
Celgene (CELG) - Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain
US$ 140.00
... Apremilast (PR, Psoriasis, PsA), and label and geographic expansion of marketed products – Revlimid, Vidaza, and ABRAXANE (L, mBC, NSCLC; R – pancreatic cancer, PDUFA: Sept. 21, 2013 ... detail please read our report on Celgene released on 2nd Sept. 2013, titled, "Label Expansion of Marketed Product and Newly Drug ...
September 2013
6 pages
Onconova Therapeutics (ONTX) -Near-Term Catalysts = Upside Still!
US$ 200.00
Onconova Therapeutics (ONTX) debut on NASDAQ (IPO: ... in pts with 2nd-line Higher Risk MDS vs. less than six months offered ... ). Our risk reward analysis indicates that ONTX's lead drug, Estybon (Rigosertib/ ON ... our report on Onconova released on 30th August 2013, titled, "Near-Term Catalysts = Upside Still!"
August 2013
11 pages
KYORIN, Flutiform Will Make its Japanese Debut Soon - A game changer for Kyorin!
US$ 200.00
... PAFSC committee recommendation, Flutiform (Fluticasone propionate + formoterol) fixed dose combination is likely to get Japanese approval in September. It will be the third ... MDI (Chart 1) and Symbicort Trubohaler. Key advantage with Flutiform is its faster onset of action which gives rapid relief from ...
August 2013
5 pages
Novartis, 2013 Outlook revised but below expectations
US$ 90.00
Novartis reported strong 2Q-2013 financial results due to the absence of Diovan generics in the US. For the same reason, Novartis has revised ... its earning guidance for the full year 2013. It ... low-single digit rate. We see the revision in guidance as inadequate and not reflective of ...
August 2013
3 pages
Merck – One timers and Forex weigh on Merck’s guidance
US$ 90.00
MRK reported its 2Q 2013 results: the net sales decline by 11% ($11.0b) including negative foreign exchange impact by 3% compared to last year. Company reiterated its 2013 non-GAAP EPS guidance ($3.45 and $3.55) while revised its GAAP EPS to be between $1.84 and $2.05 (previous $1.92-2.16). MRK expects its ...
August 2013
1 pages
Merck -Suvorexant delayed but no additional studies required is a sigh of relief
US$ 90.00
FDA recently issued a complete response letter to MRK’s Suvorexant. As per the complete response letter, the USFDA will need ... not be approved. We see the launch timelines delayed by atleast 12 to 18 months. In case of the 10mg dose Merck would have to conduct an additional stability study ...
July 2013
1 pages
Acorda Therapeutics - Pipeline and Label Expansion of AMPYRA- Drivers of Growth
US$ 140.00
Stable sales from marketed products, maturing pipeline and focus on targeting unmet needs in CNS diseases- Acorda (ACOR) has not disappointed its investors ... detail, please read our report released on June 06, 2013, titled, “Acorda Therapeutics - Pipeline and Label Expansion of AMPYRA- Drivers of Growth”.
June 2013
3 pages
MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth
US$ 140.00
Licensing of un-partnered early programs and the clinical data of its maturing therapeutic antibody pipeline are future drivers of Morphosys (MOR). After selling ... detail, please read our report released on June 05, 2013, titled, “MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth”.
June 2013
5 pages
ASCO ‘13 - Promise of Novel Targets/Technologies to Unfold At ASCO 2013
US$ 140.00
... / BiTE) for Hematological Malignancies and Solid tumors will be highlighted at ASCO. These include Amgen’s T-VEC (PhIII), Blinatumomab (PhII/III); Gilead ... detail, please read our report released on May 29, 2013, titled, “ASCO ‘13 - Promise of Novel Targets/Technologies to Unfold ...
May 2013
12 pages
Halozyme – HyQvia Approval in EU and Upcoming milestones = Upside
US$ 140.00
... drugs) has gained 50% of market share in 16 months of launch showing acceptability of Halozyme’s (HALO) ENHANZE platform (recombinant human hyaluronidase, rHuPH20 use in the ... detail, please read our report released on May 24, 2013, titled, “HyQvia Approval in EU and Upcoming milestones = Upside”.
May 2013
4 pages
Para IV Plus Database
US$ 8,000.00
... undisclosed settlement dates, based on available facts. In other words, Para IV Plus is not merely a database but is a tool with in-depth insights for every ... gives list of potential API buyers To a pharma company desirous of banking on the Para IV litigations, this tool will help them strategize their entry ...
April 2013
Japan Pharma Database
US$ 15,000.00
Pricing: Japan Database: $15,000/- subscription p/a Formulating a competitive landscape of various therapeutic classes in Japan is challenging viz a viz the US and EU markets ... reliable Source in public domain 5. Large contribution of ‘Japan Only’ products - difficult to make competitive landscapes for overseas ...
April 2013
ENDOCYTE - Small and Powerful Targeted Therapy!
US$ 140.00
Endocyte’s (ECYT) SMDC technology platform and drug pipeline caught investor’s ... our initiation report released on 19th April, 2013 on ECYT titled “Small and Powerful Targeted Therapy!
April 2013
11 pages
Xtandi- The Real Potential and the Astellas Part!
US$ 500.00
Xtandi- The Real Potential and the Astellas Part! Expectations that Xtandi (Enzalutamide, Approved, Prostate Cancer) is going to bring a paradigm shift to ... Although, the clinical profile of Xtandi (steroid free regimen, better safety and efficacy than Zytiga) carries potential to compete with Casodex/Zytiga ...
April 2013
12 pages
ENANTA PHARMA - Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!
US$ 140.00
... acquisition of Pharmasset in 2011 and ABBV through its alliance with Enanta (ENTA) in 2006. Gilead’s Sofosbuvir (PhIII, PMI) in combination with RBV ... our initiation report released on 17th April, 2013 on ENTA titled “Debut of a Star- 2nd in the Oral IFN free HCV Drug Race ...
April 2013
8 pages